Hunan Fangsheng Pharmaceutical Co., Ltd. (SHA:603998)

Market Cap	4.22B +0.1%
Revenue (ttm)	1.79B +1.9%
Net Income	306.52M +12.2%
EPS	0.70 +12.9%
Shares Out	439.08M
PE Ratio	13.74
Forward PE	11.59
Dividend	0.45 (4.70%)
Ex-Dividend Date	May 29, 2026

Volume	2,058,100
Open	9.54
Previous Close	9.62
Day's Range	9.45 - 9.62
52-Week Range	9.39 - 13.50
Beta	0.29
Analysts	Strong Buy
Price Target	15.32 (+60.08%)
Earnings Date	Aug 28, 2026

About SHA:603998

Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infective drugs. The company's main products include Xuesetong dispersible tablets, Xuesetong tablets, Garcinia bone-strengthening tablets, Dieda Huoxue ca...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 1,868
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603998

Financial Performance

In 2025, SHA:603998's revenue was 1.75 billion, a decrease of -1.75% compared to the previous year's 1.78 billion. Earnings were 306.39 million, an increase of 20.05%.

Analyst Summary

According to 2 analysts, the average rating for 603998 stock is "Strong Buy." The 12-month stock price target is ¥15.32, which is an increase of 60.08% from the latest price.

Price Target

¥15.32

(60.08% upside)

Analyst Consensus: Strong Buy